Abstract:Poly (ADP-ribose) polymerases (PARP) are a family of nuclear protein enzymes involved in the DNA damage response. The role of PARP-1 in base excisional repair has been extensively characterized. More recent in vitro studies additionally implicate a role for PARP-1 in facilitating homologous recombination and nonhomologous end-joining. The more faithful process of homologous recombination repair of double-stranded DNA breaks involves localization of BRCA-1 and BRCA-2 to sites of DNA damage, resection of the double-stranded break, and gap-filling DNA synthesis using the homologous sister chromatid as a template. Simultaneous dysfunction of both DNA repair pathways decreases the ability of cells to compensate, and forms the basis for the concept of synthetic lethality. Treatment strategies, thus far, have focused on two main principles: (i) exploitation of the concept of synthetic lethality in homologous recombination-deficient tumors, primarily in breast and ovarian cancer patients with BRCA mutation, and (ii) as radiosensitizers and chemosensitizers. BRCA deficiency accounts for only a fraction of dysfunction in homologous recombination repair. Epigenetic alterations of BRCA function and defects within the Fanconi anemia pathway also result in defective DNA repair. Rational therapeutic combinations exploiting alternate mechanisms of defective DNA repair, abrogation of cell-cycle checkpoints, and additional functions of PARP-1 present novel opportunities for further clinical development of PARP inhibitors. On the basis of the results of clinical studies of PARP inhibitors thus far, it is imperative that future development of PARP inhibitors take a more refined approach, identifying the unique subset of patients that would most benefit from these agents, determining the optimal time for use, and identifying the optimal combination partner in any particular setting.

PARP inhibition: PARP1 and beyond

Potential Biomarkers Of Poly (Adp-Ribose) Polymerase Inhibitors For Cancer Therapy

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics

The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions

Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases

PARP1: Structural insights and pharmacological targets for inhibition

Patents on PARP-1 Inhibitors for the Management of Cancer from 2017-2023

PARP1 Inhibitors: Antitumor Drug Design

The role of PARP in DNA repair and its therapeutic exploitation

Molecular Pathways: Targeting PARP in Cancer Treatment

PARP Molecular Functions and Applications of PARP Inhibitors in Cancer Treatment

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs

PARP inhibitors for anticancer therapy

The recent advance and prospect of poly(ADP-ribose) polymerase inhibitors for the treatment of cancer

Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities

A review of PARP inhibitors: from bench to bedside

Epigenetic Insights on PARP-1 Activity in Cancer Therapy

Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function